Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis

Goon, Peter Kin Cho; Lim, Hai-Yee; Summerfield, Liz; Banfield, Cedric Charles; Sudhoff, Holger; Mallett, Dick

Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis

Goon PKC, Lim H-Y, Summerfield L, Banfield CC, Sudhoff H, Mallett D (2021)
International Journal of Dermatology 60(8): e319-e320.

Zeitschriftenaufsatz | Veröffentlicht | Englisch

Download

Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!

DOI

https://doi.org/10.1111/ijd.15560

Autor*in

Goon, Peter Kin Cho; Lim, Hai-Yee; Summerfield, Liz; Banfield, Cedric Charles; Sudhoff, Holger^UniBi ; Mallett, Dick

Einrichtung

Medizinische Fakultät OWL > AG 202 Hals-Nasen-Ohrenheilkunde

Erscheinungsjahr

2021

Zeitschriftentitel

International Journal of Dermatology

Band

60

Ausgabe

8

Seite(n)

e319-e320

ISSN

0011-9059

eISSN

1365-4632

Page URI

https://pub.uni-bielefeld.de/record/2953797

Zitieren

Goon PKC, Lim H-Y, Summerfield L, Banfield CC, Sudhoff H, Mallett D. Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology. 2021;60(8):e319-e320.

Goon, P. K. C., Lim, H. - Y., Summerfield, L., Banfield, C. C., Sudhoff, H., & Mallett, D. (2021). Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology, 60(8), e319-e320. https://doi.org/10.1111/ijd.15560

Goon, Peter Kin Cho, Lim, Hai-Yee, Summerfield, Liz, Banfield, Cedric Charles, Sudhoff, Holger, and Mallett, Dick. 2021. “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”. International Journal of Dermatology 60 (8): e319-e320.

Goon, P. K. C., Lim, H. - Y., Summerfield, L., Banfield, C. C., Sudhoff, H., and Mallett, D. (2021). Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology 60, e319-e320.

Goon, P.K.C., et al., 2021. Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology, 60(8), p e319-e320.

P.K.C. Goon, et al., “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”, International Journal of Dermatology, vol. 60, 2021, pp. e319-e320.

Goon, P.K.C., Lim, H.-Y., Summerfield, L., Banfield, C.C., Sudhoff, H., Mallett, D.: Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis. International Journal of Dermatology. 60, e319-e320 (2021).

Goon, Peter Kin Cho, Lim, Hai-Yee, Summerfield, Liz, Banfield, Cedric Charles, Sudhoff, Holger, and Mallett, Dick. “Real‐world experience and analyses of the performance of ixekizumab as first‐line biologic agent versus second‐line (or higher) biologic agent in the treatment of chronic plaque psoriasis”. International Journal of Dermatology 60.8 (2021): e319-e320.

Daten bereitgestellt von European Bioinformatics Institute (EBI)